EG-COVII

EyeGene Inc. · Phase 1 active Biologic

At a glance

Generic name	EG-COVII
Sponsor	EyeGene Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EG-COVII CI brief — competitive landscape report
EG-COVII updates RSS · CI watch RSS
EyeGene Inc. portfolio CI